29th International Prostate Cancer Update (IPCU29)
The International Prostate Cancer Update conference is a multi-day CME conference focused on prostate cancer treatment updates with expert international faculty. In January 2019, IPCU 29 will continue this tradition of nearly three decades by featuring short expert lectures, interactive audience response technology, panel and roundtable discussions, point-counterpoint debates, and presentation and review of difficult case reports. This well-regarded conference is led by more than two dozen expert faculty, and it is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer.
The goal of this educational program is to equip healthcare professionals involved in the diagnosis and treatment of prostate cancer with up-to-date clinical knowledge and previews of upcoming research and technologies, and to provide them the tools they will need to best treat their patients with prostate cancer. The IPCU 29 program will discuss the spectrum of treating prostate cancer from initial diagnosis to treating advanced and metastatic disease. Our educational design aims to give physicians exposure to a comprehensive review of a wide range of methods for treating prostate cancer patients, to provide them with the opportunity to discuss the issues with peers and experts, and enable them to apply what they learn to their individual practices.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and Carden Jennings Publishing. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this live activity for a maximum of 22.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and management of prostate cancer
Upon completion of this program, participants will be able to:
• Discuss the experiences of both urologists and oncologists in various practice settings to improve patient outcomes by integrating a team approach to treatment.
• Evaluate biomarkers, biopsy techniques, and MRI advancements in the treatment of localized prostate cancer.
• Assess strategies using hormonal, cytotoxic, and immunotherapeutic agents for advanced and castration-resistant prostate cancer.
• Appraise the newer antiandrogens as options for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).
• Investigate ways to incorporate the improvement in men’s health strategies like nutrition and exercise into the treatment of prostate cancer.
Wednesday, January 23, 2019
11:00AM - 6:00PM 3rd International Bladder Cancer Update
7:00PM - 8:00PM IBCU/IPCU/LUGPA Welcome Reception - Upstairs Library
Thursday, January 24, 209
7:00AM - 7:10AM IPCU Welcome and Opening Remarks
7:10AM - 7:20AM The Present and Future of LUGPA
7:20AM - 11:00AM Session I: Preventions, Screening and Biomarkers
11:00AM - 3:30PM Poster Sessions - Open Viewing
4:00PM - 5:30PM Session II: LUGPA Lecture Series
5:45PM - 7:30PM Session III: Localized Disease: Alternative Technologies - Part 1
Friday, January 25, 2019
7:00AM - 9:00AM Session IV: Localized Disease: Alternative Technologies - Part 2
9:20AM - 10:30AM Session V: Tools for building a Better Urology Practice
ALL DAY Poster Sessions - Opening Viewing
4:00PM - 5:30PM Session VI: Men's Health
6:00PM - 7:00PM Moderated Poster Session
Saturday, January 26, 2019
7:45AM - 8:30AM Industry-Supported Presentation
8:30AM - 11:00AM Session VII: Advanced Disease
4:00PM - 5:30PM Session VIII: Advanced and Metastatic Prostate Cancer
5:30PM - 5:45PM Next Generation Learning: The Key Take Home Message from IPCU 29
Program Director: E. David Crawford, MD
DISCLOSURE OF CONFLICTS OF INTEREST
It is the policy of the Medical College of Wisconsin to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, the MCW identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of the activity. Conflicts are resolved by MCW to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.
The employees of Carden Jennings Publishing, Company have no financial relationships to disclose.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and Carden Jennings Publishing. The Medical College of Wisconsin is accredited with commendation by the ACCME to provide continuing medical education for physicians.
MCW designates this live activity for a maximum of 14.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- 14.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 14.00 Hours of ParticipationHours of Participation credit.